Gepotidacin, an oral bacterial type II topoisomerase inhibitor, received FDA approval in March 2025 for uncomplicated urinary tract infections under the brand Blujepa and remains under FDA review for gonorrhea. The molecule targets both DNA gyrase and topoisomerase IV via a distinct binding mode, positioning it to overcome common fluoroquinolone resistance mechanisms. Developers and clinicians highlight gepotidacin’s potential to spare gut microbiota and reduce class‑wide safety concerns, while regulators continue to evaluate its role in sexually transmitted infections. The approval adds a new oral option to the limited outpatient antibiotic armamentarium.